Related references
Note: Only part of the references are listed.Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes
Mona M. Hosseini et al.
LEUKEMIA (2018)
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2018)
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial
John Mascarenhas et al.
JAMA ONCOLOGY (2018)
Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy
Jack W. Singer et al.
Oncotarget (2018)
Managing patients with myelofibrosis and low platelet counts
Haifa Kathrin Al-Ali et al.
ANNALS OF HEMATOLOGY (2017)
Janus kinase inhibitors in dermatology: A systematic review
Rony Shreberk-Hassidim et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Mechanisms of Skin Toxicity Associated with Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators
Falgun Shah et al.
CELL CHEMICAL BIOLOGY (2017)
ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP
Taru Muranen et al.
CANCER RESEARCH (2016)
Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia
Avery Polk et al.
CLINICAL CANCER RESEARCH (2016)
Developments with investigational Janus kinase inhibitors for rheumatoid arthritis
Luca Semerano et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Immunological off-target effects of imatinib
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
Qingshan Yang et al.
CLINICAL CANCER RESEARCH (2015)
Elucidating Mechanisms of Toxicity Using Phenotypic Data from Primary Human Cell Systems-A Chemical Biology Approach for Thrombosis-Related Side Effects
Ellen L. Berg et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial
Animesh Pardanani et al.
JAMA ONCOLOGY (2015)
Therapeutic Targeting of the JAK/STAT Pathway
Saara Aittomaki et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2014)
Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
Sara C. Meyer et al.
CLINICAL CANCER RESEARCH (2014)
Update on Janus Kinase Antagonists in Inflammatory Bowel Disease
Brigid S. Boland et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2014)
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)
T. Zhou et al.
LEUKEMIA (2014)
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Pietro Ciceri et al.
NATURE CHEMICAL BIOLOGY (2014)
Characterization of novel PI3Kδ inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies
Philipp Haselmayer et al.
FRONTIERS IN IMMUNOLOGY (2014)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
Annkristin Heine et al.
BLOOD (2013)
Regulation of IL-17A Production Is Distinct from IL-17F in a Primary Human Cell Co-culture Model of T Cell-Mediated B Cell Activation
Andrew C. Melton et al.
PLOS ONE (2013)
Practical management of patients with myelofibrosis receiving ruxolitinib
Claire Harrison et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Building Predictive Models for Mechanism-of-Action Classification from Phenotypic Assay Data Sets
Ellen L. Berg et al.
JOURNAL OF BIOMOLECULAR SCREENING (2013)
Development of Antibiotic Activity Profile Screening for the Classification and Discovery of Natural Product Antibiotics
Weng Ruh Wong et al.
CHEMISTRY & BIOLOGY (2012)
Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The JAK/STAT Pathway
Douglas A. Harrison
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2012)
Chemical target and pathway toxicity mechanisms defined in primary human cell systems
Ellen L. Berg et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2010)
Colony-stimulating factor-1 in immunity and inflammation
V Chitu et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases
KE Panteli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models
EJ Kunkel et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2004)
An integrative biology approach for analysis of drug action in models of human vascular inflammation
EJ Kunkel et al.
FASEB JOURNAL (2004)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Share Paper
